Better data framework needed to improve rare disease diagnostic rates

April 16, 2020

A better framework for the reanalysis of genetic data, a game-changing process which could improve diagnostic rates by up to 32 per cent, was needed, a new study has found.

The research, led by the Murdoch Children's Research (MCRI) and the University of Melbourne and published in Familial Cancer, found considerable variation in the ways that reanalysis of patient data was initiated, which raised concerns about the responsibilities of laboratories and clinicians, as well as patients' abilities to advocate for themselves.

The reanalysis process sees laboratories re-run previously analysed genomic data to check for new genes associated with particular conditions and also new variants in genes previously reported.

Lead researcher MCRI's Dr Danya Vears said previous studies have shown that despite the high diagnostic yield associated with genomic sequencing (up to 68 per cent depending on the genetic condition), a sizable proportion of patients still do not receive a genetic diagnosis at the time of the initial analysis.

Dr Vears said reanalysis of genomic sequencing data could potentially change treatment or management, particularly in rare disease and inherited cancer cases. Yet, there is currently no onus on laboratories to reanalyse data.

"Studies show that systematic data reanalysis leads to considerable increases in genetic diagnosis rates between 4 and 32 per cent. Yet it is time intensive and is not currently feasible for most laboratories to implement," she said.

"Few policies address whether laboratories have a duty to reanalyse and it is unclear until now how this has impacted clinical practice."

The study interviewed 31 genetic health professionals (genetic counsellors and clinical geneticists) across Europe, Australia and Canada about their experiences with data reanalysis and reinterpretation practices after requesting genomic sequencing for their patients. It identified that a combination of patient-, clinician-, and laboratory-initiated reanalysis practice models, were used to trigger reanalysis of patient data.

Dr Vears said the most common was a patient-initiated model, where clinicians instruct patients to return to the genetic service for reassessment after a period of time or if new information came to light.

"Some of our participants felt that this system was working quite well and that patients were returning," she said.

"Yet others raised questions around patients' abilities to proactively request this service. This could be due to their lack of understanding of what a negative result might mean or because it places additional pressure on patients or families to remember to return when they are already dealing with a complex medical situation."

Genetic health professionals felt a laboratory-initiated model would be ideal, but many acknowledged the technology to make this a reality was not yet available. None of the participants indicated that reanalysis within their service relied solely on the clinician to initiate the process.

Dr Vears said, in many cases, the initiation of reanalysis did not have a clear pathway and could occur through multiple channels, which could lead to confusion.

"Regardless of the model that a genetic service adopts, roles and responsibilities need to be clearly outlined so patients do not miss the opportunity to receive ongoing information about their genetic diagnosis," she said.

Dr Vears said translating the power of genomic sequencing from the research context into clinical care was currently one of the major goals of researchers and health-care providers, particularly in areas such as rare disease and inherited cancers.
Researchers from KU Leuven in Belgium, Leuven Institute for Human Genetics and Society in Belgium and McGill University in Canada also contributed to the findings.

Publication: Danya F Vears, Karine Sénécal and Pascal Borry. 'Genetic health professionals' experiences with initiating reanalysis of genomic sequence data,' Familial Cancer. DOI: 10.1007/s10689-020-00172-7

Available for interview:

Dr Danya Vears

Murdoch Childrens Research Institute

Related Genetic Data Articles from Brightsurf:

Future of genomics at risk without greater public trust in how genetic data is shared
The largest ever survey on global public attitudes towards genomic research and data sharing suggests that work is needed to raise levels of public trust in how genetic data is used in order for that data to fulfil its promise to advance human health and medicine.

Wildlife trade threats: The importance of genetic data in saving an endangered species
In a new study, published in the scientific journal Nature Conservation, a research team analyses the genetic diversity of the endangered Four-eyed turtle, a species that has fallen victim to the growing wildlife trade in Vietnam.

Ups and downs in COVID-19 data may be caused by data reporting practices
As data accumulates on COVID-19 cases and deaths, researchers have observed patterns of peaks and valleys that repeat on a near-weekly basis.

DNA riddle unravelled: How cells access data from 'genetic cotton reels'
With so much genetic information packed in such a tiny space, how cells access DNA when it needs it is something of a mystery.

More than half of Americans want money, control in exchange for genetic data
As people become more aware of privacy concerns and the ways in which genomic database companies are profiting from their data, their expectations for compensation and control may increase, according to researchers at Penn State and Cornell University.

Nature Gene Therapy publishes preclinical data of Ocugen's OCU400 genetic modifier
Ocugen, Inc., a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, announced today the publication in Nature Gene Therapy of preclinical data of nuclear hormone receptor gene NR2E3 as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases.

Calculating genetic links between diseases, without the genetic data
In a new study, data scientists from the University of Chicago estimated heritability and mapped out relationships among thousands of diseases using data from electronic health records.

Scientists develop method to standardize genetic data analysis
MIPT researchers have collaborated with Atlas Biomedical Holding and developed a new bioinformatics data analysis method.

Third-party genetic genealogy site is vulnerable to compromised data, impersonations
University of Washington researchers have found that the third-party genealogy site GEDmatch is vulnerable to multiple kinds of security risks.

ASHG asserts core genetic data privacy principles for all research and funding arenas
The American Society of Human Genetics (ASHG) today affirmed the crucial role of genetic and genomic data sharing to advance medicine and health research, and asserted core principles about privacy protections that should apply to all human genetics and genomics research regardless of funding source.

Read More: Genetic Data News and Genetic Data Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to